The company management believes there are a lot of things to be done to be compliant with the US drug regulator’s norms.
“I do not support a sabotage theory for the Toansa plant.
"I have never said the problem is on account of the voluntary retirement scheme.
"This is the official position that I have maintained. I will maintain that,” Chief Executive and Managing Director Arun Sawhney said after meeting FDA Commissioner Margaret Hamburg on Tuesday.
Sawhney and Ranbaxy Chairman Tsutomu Une were part of the pharmaceutical sector delegation that met Hamburg here.
Officials in the Drug Controller General of India’s office had said company executives who met the regulator following the FDA’s action on the Toansa factory had indicated some disgruntled employees offered voluntary retirement were behind a sabotage leading to the US ban on imports from that plant.
The Toansa plant was supplying 70 per cent of Ranbaxy’s
Are Ranbaxy drugs available in India safe?
Why Daiichi is taking Malvinder Singh to court
Keep us in loop before any FDA swoop, India tells US
Ranbaxy sets aside Rs 257.4 cr for impact of USFDA ban
India raises concerns over FDA actions on domestic drug firms